P.D.: Desde Junio del 2012 SYL040012 esta en Fase II ... en Mayo de este podrían saberse datos intermedios ya de esta Fase II ... y Estimated Study Completion Date : December 2013 ... con lo que sin hacer practicamente ruido alguno Sylentis ( Zeltia ) Podría tener un Farmaco a las puertas de la Definitiva Fase III .
*.- Está indicado para el Tratamiento de la Hipertensión Ocular Asociada a Glaucoma.
*.- SYL040012 es una Entidad Química que se engloba dentro de los RNA de Interferencia.
*.- Sylentis se Encuentra entre las Cinco primeras compañías a Nivel Mundial con Ensayos Clínicos de RNAi.
*******************************************
A look at the safety and efficacy of various therapies for the disease, from pharmaceuticals to surgical implants.
Mark B. Abelson, MD, CM, FRCSC, FARVO, Robert David, MD, Aron Shapiro and James McLaughlin, PhD, Andover, Mass.
1/17/2013
Primary open-angle glaucoma is a condition with a large number of treatment strategies, from drugs to devices to surgical interventions. The most effective drugs are available as generics or will be coming off patent soon. The stability of the therapeutic choices available (there hasn’t been a new class of glaucoma drug in more than 15 years) might lead you to think that it’s a disease that is under control with existing treatments, yet it remains a disease without a cure, a disorder with a significant ocular morbidity, and is the second-leading global cause of blindness. Of the 60 million people with this disease worldwide,1 15 percent will have a severe degree of permanent visual impairment.
...
IOP-lowering Drugs :
... Another dose-escalation trial is under way for SYL040012 (Sylentis). The Sylentis compound is an RNAi-based compound designed to target the same b-adrenergic pathway targeted by timolol. Instead of acting as a traditional receptor antagonist however, SYL040012 blocks the pathway by inhibiting biosynthesis of the receptor protein. ...